929088-03-9

Basic information

• Product Name: 3-[4-(2-{2-[2-(2-{2-[4-(3,5-dioxo-hexyl)-phenylcarbamoyl]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-phenyl]-N-[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-N-methyl-propionamide
• CAS NO: 929088-03-9
• Molecular Weight: 994.132
• Mol File: 929088-03-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-[4-(2-{2-[2-(2-{2-[4-(3,5-dioxo-hexyl)-phenylcarbamoyl]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-phenyl]-N-[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-N-methyl-propionamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-(2-{2-[2-(2-{2-[4-(3,5-dioxo-hexyl)-phenylcarbamoyl]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-phenyl]-N-[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-N-methyl-propionamide(929088-03-9)
• EPA Substance Registry System: 3-[4-(2-{2-[2-(2-{2-[4-(3,5-dioxo-hexyl)-phenylcarbamoyl]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-phenyl]-N-[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-N-methyl-propionamide(929088-03-9)

Safety Data

• Hazardous Substances Data: 929088-03-9(Hazardous Substances Data)

Upstream product

• 518044-32-1 tert-butyl 3-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)propanoate 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 123-54-6 acetylacetone 
• 23795-02-0 3-(4-hydroxy-phenyl)-propionic acid ethyl ester 
• 929087-99-0 3-{2-[2-(2-{2-[4-(2-ethoxycarbonyl-ethyl)-phenoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-propionic acid 
• 782475-33-6 C₁₆H₂₁NO₆ 
• 782475-32-5 4-{2-[2-(2-Methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylamine 
• 192650-25-2 6-(4-nitrophenyl)hexane-2,4-dione 
• 929088-01-7 3-(4-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-phenyl)-propionic acid 

Relevant articles and documents

Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies

Aryl sulfonamide-based endothelin antagonists were synthesized and covalently linked to the reactive lysine of the m38C2 antibody to create a series of CovX-Bodies. These chemically programmed antibodies behaved as potent endothelin receptor antagonists in vitro and had antitumor efficacy in a prostate cancer xenograft model which, on a molar basis, far exceeded the activity of the parent small molecule.